US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
pharma · severe uncontrolled asthma · mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD) · GENB
Generate Biomedicines
Generate Biomedicines drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Somerville, USA HQ
325 Employees
Public company Type
GENB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Somerville, USA
- Employees
- 325
- Programs
- 8
- Drugs
- 7
- Patents
- 1
Generate Biomedicines pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Generate Biomedicines drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Generate Biomedicines in public FDA and regional records.
-
Development asset linked to Generate Biomedicines in public FDA and regional records.
-
Development asset linked to Generate Biomedicines in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Generate Biomedicines's portfolio.
-
Development asset linked to Generate Biomedicines in public FDA and regional records.
-
US regulatory status: approved.